Access Pharmaceuticals Provides Update on Clinical Development Plan of... (gemcitabine. As a result of the ProL...)

Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac

Date:8/20/2007

gemcitabine.

"As a result of the ProLindac results to date, we have put plans in place for ProLindac manufacturing scale-up in advance of starting these additional clinical trials and enrolling additional patients," added Stephen R. Seiler, Access' Chief Executive Officer. "We believe the enhanced safety profile of ProLindac will allow for more efficient and longer delivery of DACH platinum- based therapy with consequential patient benefit."

ProLindac is a novel DACH platinum prodrug which has been shown to be active in a wide variety of solid tumors in both preclinical models and in human trials. Access believes that ProLindac's unique molecular design potentially could eliminate some of the toxic side effects seen in the currently marketed DACH platinum, Eloxatin, which has sales in excess of $2 billion.

Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes propriety products for the treatment and supportive care of cancer patients. Access' products include ProLindac(TM), currently in Phase II clinical testing of patients with ovarian cancer and MuGard(TM) for the treatment of patients with mucositis. The Company also has other advanced drug delivery technologies including vitamin-mediated targeted delivery and oral drug delivery. For additional information on Access Pharmaceuticals, please visit our website at http://www.accesspharma.com.

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that involve risks and uncertainties including, but not limited to statements relating to the safety profile of Prolindac, our plans to commence a further clinical trial in 4Q07 or 1Q08, the pharmacological effects of Prolindac, our ability to implement combination drug trials, that the full potential for
'/>"/>

SOURCE Access Pharmaceuticals, Inc.

0

GOOD

Page: 1 2 3 4
Related medicine technology :

1. PromegaExpress Expands Easy Access to Products with New Cabinet
2. Access and Somanta Announce Data to be Presented on Angiolix at ASCO Oncology Conference
3. Access Pharmaceuticals Announces Poster Presentations on ProLindac at the American Association for Cancer Research 2007 Annual Meeting
4. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
9. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
10. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings

Post Your Comments:

Access Pharmaceuticals Provides Update on Clinical Development Plan of...(gemcitabine. As a result of the ProL...),Health